Company newsForm 8-K
AbCellera Biologics ABCL
AbCellera Biologics appoints Lynn Seely to its board of directors
Seely is president and CEO of Lyell Immunopharma Inc. and was previously CEO of Myovant Sciences Inc.
GetSignal
AbCellera Biologics said its board appointed Lynn Seely, M.D., as a Class III director on June 30, 2026. The board determined she is independent under NASDAQ rules and the company's governance guidelines, and she has no committee seat.
The company said she will serve until the 2029 annual meeting of shareholders.
Key facts
- Position
- Class III director
- Appointed
- June 30, 2026
- Term ends
- 2029 annual meeting of shareholders
- Committee seats
- None
Source: Form 8-K filed July 6, 2026. The company's release as filed with the SEC.
Written by GetSignal with AI from the company's SEC filing. How we make news
Not investment advice.
More company news
AbCellera Biologics first, then the newest- AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants
ABCL · AbCellera Biologics · Form 8-K · Aug 13, 2026
- AbCellera Biologics shareholders elect two Class III directors
ABCL · AbCellera Biologics · Form 8-K · Jun 12, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
